Previous 10 | Next 10 |
Express (EXPR) +131%.TS Innovation Acquisitions (TSIA) +82% on merger agreement with Latch Inc..Aemetis (AMTX) +60%.Spartan Acquisition Corp. II (SPRQ) +51% on entering into business combination agreement with Sunlight.VYNE Therapeutics (VYNE) +40%.GameStop (GME) +43%.Aurinia Pharma...
The FDA has approved LUPKYNISTM (voclosporin) from Aurinia Pharmaceuticals Inc. (AUPH) as a treatment for adults with active lupus nephritis (“LN”) in combination with a background immunosuppressive therapy regimen.Aurinia rose ~14.1% during the five-day period leading...
- LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - LUPKYNIS demonstrated significantly improved renal response rates compared to ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissio...
AUPH stock has fallen on two recent developments. I analyze these and argue that the second, a new licensing agreement, is not negative, rather it's a positive for stockholders. I also review some of the secondary endpoint data which I believe will help accelerate the adoption of ...
Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks. Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug Voclosporin. Voclosporin approval by the FDA is almost assured thanks to the very good ph...
Aurinia Pharmaceuticals (AUPH) has entered into a collaboration and license agreement with Otsuka Pharmaceutical for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis ((LN)) in the European Union ((EU)), Japan, U.K., Russia, Switzerland, Norway, Be...
- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments - - Agreement includes royalties of up to 20 percent on net sales payable to Aurinia - Aurinia Pharmaceuticals Inc. (NASDAQ:...
- State-of-the-Art Monoplant Will Provide Cost and Production Efficiency and Secure Active Pharmaceutical Ingredient (API) Supply for Future Commercial Demand - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...